MBA考试

【单选题】In 2010, a federal judge shookAmerica’s biotech industry to its core.Companies had won patents for isolatedDN
A、for decades--by 2005 some 20% of human genes were patente
D、But in March 2010 a judge ruled that genes were unpatentable.Executives were violently agitate
D、TheBiotechnology Industry OrganisationBIO), a trade group, assured members that this was just a "preliminary step" in a longer battle.
On July 29th they wererelieved, at least temporarily.
A、federal appeals court overturned the prior decision, ruling that Myriad Genetics could indeed hold patents to two genes that help forecast a woman’ s risk of breast cancer. The chief executive of Myriad, a company in Utah, said the ruling was a blessing to firms and patients alike.
But as companies continue their attempts at personalised medicine, the courts will remain rather busy. The Myriad ease itself is probably not over.Critics make three main arguments against gene patents: a gene is a product of nature, so it may not be patented; gene patents suppress innovation rather than reward it; and patents’ monopolies restrict access to genetic tests such as Myriad’ s.
A、growing number seem to agree. Last year a federal task-force urged reform for patents related to genetic tests. In October theDepartment of Justice filed a brief in the Myriad case, arguing that an isolatedDN
A、molecule "is no less a product of nature." than are cotton fibres that have been separated from cotton seeds. "
Despite the appeals court’ s decision, big questions remain unanswere
D、For example, it is unclear whether the sequencing of a whole genomeviolates the patents of individual genes within it. The case may yet reach the SupremeCourt.
As the industry advances, however, other suits may have an even greater impact.Companies are unlikely to file many more patents for humanDN
A、molecules--most are already patented or in the public domain. Firms are now studying how genes interact, looking for correlations that might be used to determine the causes of disease or predict a drug’ s efficacy"Companies are eager to win patents for "connecting the dots," explains Hans Sauer, a lawyer for theBIO.
Their success may be determined by a suit related to this issue, brought by the MayoClinic, which the SupremeCourt will hear in its next term. TheBIO recently held a convention which included sessions to coach lawyers on the shifting landscape for patents.Each meeting was packe
D、
Those who are against gene patents believe that ______.
A、genetic tests are not reliable
B．only man-made products are patentable
C．patents on genes depend much on innovation

D、courts should restrict access to genetic tests

网考网参考答案：B
网考网解析：
细节题。根据题干中的Those who are against gene patents定位到第三段第三句。该句指出了批评人士反对基因专利的三点理由。第一个理由是：基因是自然产品，因此它不能被申请专利。也就是说，只有非自然产品才能申请专利，因此B项“只有人造产品才具有专利性”为正确答案。 document.getElementById("warp").style.display="none"; document.getElementById("content").style.display="block"; 查看试题解析出处>>